Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics stock jumps after ‘great' trial of weight-loss drug
04:19am, Monday, 04'th Nov 2024
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
10:36pm, Sunday, 03'rd Nov 2024
Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.. The post Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data appeared first on
Viking Therapeutics to Participate at Upcoming Investor Conferences
04:05pm, Thursday, 31'st Oct 2024
SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
07:02am, Thursday, 31'st Oct 2024
The U.S. presidential election will be held on November 5, 2024, but there's another event that investors may want to vote on before the election. From November 3 through November 6, the Obesity Socie
This High-Flying Stock Just Became a Better Buy
05:45am, Thursday, 31'st Oct 2024
It might not be too late to get in on the party.
Viking Therapeutics: Lots Of Positives
04:20pm, Monday, 28'th Oct 2024
Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment due to its potential in a $40 billion market. The company plans to escalate V
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
04:05pm, Monday, 28'th Oct 2024
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO , Oct. 28, 2024 /PRNewswire/ -- Viking Thera
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
10:45am, Sunday, 27'th Oct 2024
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Viking Therapeutics: Q3 Earnings Report Loads A Barrage Of Catalysts
01:12pm, Friday, 25'th Oct 2024
Viking Therapeutics shows significant clinical progress in obesity, NASH, and X-ALD, with promising Phase II and preclinical data positioning it for potential market leadership. Despite operating at a
S&P 500, Nasdaq rise sharply ending 3-day losing streak; Viking Therapeutics surge, while Capri's shares slump
01:01pm, Friday, 25'th Oct 2024
US benchmark equity averages rose on Friday as the market ended a three-day losing streak. At the time of writing, the Dow Jones Industrial Average was up 0.3%, while S&P 500 rose 0.8% from the prev
Viking Therapeutics' shares soar on fresh weight-loss medication hopes
06:10pm, Thursday, 24'th Oct 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking's stock jumping on weight-loss hopes.
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
04:55pm, Thursday, 24'th Oct 2024
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.
2 Biotech Stocks Making Big Moves
01:01pm, Thursday, 24'th Oct 2024
The ever-volatile biotech sector is making noise today.
Viking Therapeutics' stock soars 18% as data on oral weight-loss drug looms
11:38am, Thursday, 24'th Oct 2024
Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings th
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
10:26am, Thursday, 24'th Oct 2024
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
